zo-1

BTZO-1 is an antioxidant response element (ARE) activator with cardioprotective activity.

BTZO-15 is a novel ARE activator, ameliorating DSS- and TNBS-induced colitis in rats.

Benzo-18-crown-6-ether (B18C6) is an organic compound used to create stable microcapsule responsive layers, which can be assembled into bilayer microcapsules. For instance, 18-Crown-6-ether is employed to prepare a responsive layer and then coated with a K+-stabilized G-quadruplex cross-linked hydrogel layer. When Mg2+ ions are present, 18-Crown-6-ether and K+ ions enable dissociation and locking with the G-quadruplex cross-linked layer, allowing for switchable controlled release of the load.

Dibenzo-18-crown-6 is a biochemical reagent that can be used as a biomaterial for life science related research and as a sulfonylation reagent for organic synthesis and drug discovery.

Benzo-15-crown-5-ether can serve as a chelating agent for sodium and potassium.

3,4-Dephostatin is an inhibitor of the interactions of CFTR-associated ligand (CAL) and PSD-95 Dlg1 ZO-1 (PDZ) domain.

Puromycin aminonucleoside (NSC-3056) increases podocyte permeability by modulating ZO-1 in an oxidative stress-dependent manner.

KY-226 is a potent inhibitor of protein tyrosine phosphatase 1B (PTP1B)(IC50: 0.25 μM,)

Ethyl-3,4-dephostatin is a novel inhibitor of the interactions of CFTR-associated ligand and PSD-95 Dlg1 ZO-1 domain.